このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Cara Therapeutics マネジメント
マネジメント 基準チェック /24
Cara Therapeutics'の CEO はChris Posnerで、 Nov2021年に任命され、 の在任期間は 2.58年です。 の年間総報酬は$ 2.92Mで、 24.9%給与と75.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.2%を直接所有しており、その価値は$ 73.14K 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と4.9年です。
主要情報
Chris Posner
最高経営責任者
US$2.9m
報酬総額
| CEO給与比率 | 24.9% |
| CEO在任期間 | 2.6yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 2.5yrs |
| 取締役会の平均在任期間 | 4.9yrs |
経営陣の近況
Recent updates
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29
Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$123m |
| Dec 31 2023 | US$3m | US$728k | -US$119m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$84m |
| Dec 31 2022 | US$3m | US$700k | -US$85m |
| Sep 30 2022 | n/a | n/a | -US$89m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$93m |
| Dec 31 2021 | US$10m | US$116k | -US$88m |
| Sep 30 2021 | n/a | n/a | US$24m |
| Jun 30 2021 | n/a | n/a | US$8m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$280k | n/a | US$8m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$302k | n/a | -US$106m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$494k | n/a | -US$74m |
報酬と市場: Chrisの 総報酬 ($USD 2.92M ) は、 US市場 ($USD 667.63K ) の同規模の企業の平均を上回っています。
報酬と収益: Chrisの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Chris Posner (54 yo)
2.6yrs
在職期間
US$2,922,469
報酬
Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.6yrs | US$2.92m | 0.20% $ 38.6k | |
| Chief Financial Officer | 1.8yrs | US$1.24m | 0.015% $ 2.8k | |
| Co-Founder & Senior Advisor | 2.6yrs | US$10.20m | データなし | |
| Chief Strategy Officer & Head of Investor Relations | 2.4yrs | データなし | データなし | |
| Chief Compliance Officer | 7.6yrs | US$1.59m | 0.15% $ 28.6k | |
| Senior Vice President of Regulatory Affairs & QA | 2.3yrs | データなし | データなし | |
| Manager of Investor Relations | no data | データなし | データなし |
2.5yrs
平均在職期間
57.5yo
平均年齢
経験豊富な経営陣: CARAの経営陣は 経験豊富 であると考えられます ( 2.5年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 5.8yrs | US$2.92m | 0.20% $ 38.6k | |
| Independent Chairman & Lead Independent Director | 13.9yrs | US$519.99k | 0.20% $ 38.4k | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Member of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 9.9yrs | US$272.49k | 0.087% $ 16.7k | |
| Independent Director | less than a year | US$376.01k | 0% $ 0 | |
| Independent Director | 4yrs | US$262.49k | 0.094% $ 18.0k | |
| Independent Director | 1.6yrs | US$254.99k | 0.059% $ 11.3k |
4.9yrs
平均在職期間
61.5yo
平均年齢
経験豊富なボード: CARAの 取締役会 は 経験豊富 であると考えられます ( 4.9年の平均在任期間)。